202 related articles for article (PubMed ID: 21727772)
1. Successful treatment of steroid-refractory autoimmune thrombocytopenia associated with Castleman disease with anti-CD-20 antibody (rituximab).
Ibrahim K; Maghfoor I; Elghazaly A; Bakshi N; Mohamed SY; Aljurf M
Hematol Oncol Stem Cell Ther; 2011; 4(2):100-2. PubMed ID: 21727772
[TBL] [Abstract][Full Text] [Related]
2. Successful treatment with the monoclonal antibody rituximab in two children with refractory autoimmune thrombocytopenia.
Pusiol A; Cesaro S; Nocerino A; Picco G; Zanesco L; Bisogno G
Eur J Pediatr; 2004 Jun; 163(6):305-7. PubMed ID: 15346911
[TBL] [Abstract][Full Text] [Related]
3. Monoclonal antibodies in the treatment of immune thrombocytopenic purpura (ITP).
Gómez-Almaguer D
Hematology; 2012 Apr; 17 Suppl 1():S25-7. PubMed ID: 22507772
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of rituximab in an aggressive form of multicentric Castleman disease associated with immune phenomena.
Ocio EM; Sanchez-Guijo FM; Diez-Campelo M; Castilla C; Blanco OJ; Caballero D; San Miguel JF
Am J Hematol; 2005 Apr; 78(4):302-5. PubMed ID: 15795923
[TBL] [Abstract][Full Text] [Related]
5. Rituximab chimeric anti-CD20 monoclonal antibody treatment for adult refractory idiopathic thrombocytopenic purpura.
Braendstrup P; Bjerrum OW; Nielsen OJ; Jensen BA; Clausen NT; Hansen PB; Andersen I; Schmidt K; Andersen TM; Peterslund NA; Birgens HS; Plesner T; Pedersen BB; Hasselbalch HC
Am J Hematol; 2005 Apr; 78(4):275-80. PubMed ID: 15795920
[TBL] [Abstract][Full Text] [Related]
6. Sustained remission of platelet counts following monoclonal anti-CD20 antibody therapy in two cases of idiopathic autoimmune thrombocytopenia and neutropenia.
Faurschou M; Hasselbalch HC; Nielsen OJ
Eur J Haematol; 2001 Jun; 66(6):408-11. PubMed ID: 11488941
[TBL] [Abstract][Full Text] [Related]
7. Effective B cell depletion with rituximab in the treatment of autoimmune diseases.
Kneitz C; Wilhelm M; Tony HP
Immunobiology; 2002 Dec; 206(5):519-27. PubMed ID: 12607727
[TBL] [Abstract][Full Text] [Related]
8. Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura.
Stasi R; Pagano A; Stipa E; Amadori S
Blood; 2001 Aug; 98(4):952-7. PubMed ID: 11493438
[TBL] [Abstract][Full Text] [Related]
9. Successful use of anti-CD20 (rituximab) in severe, life-threatening childhood immune thrombocytopenic purpura.
Bengtson KL; Skinner MA; Ware RE
J Pediatr; 2003 Nov; 143(5):670-3. PubMed ID: 14615744
[TBL] [Abstract][Full Text] [Related]
10. Anti-CD20 therapy for chronic lymphocytic leukemia-associated autoimmune diseases.
Zaja F; Vianelli N; Sperotto A; Patriarca F; Tani M; Marin L; Tiribelli M; Candoni A; Baccarani M; Fanin R
Leuk Lymphoma; 2003 Nov; 44(11):1951-5. PubMed ID: 14738149
[TBL] [Abstract][Full Text] [Related]
11. Cytokine changes during rituximab therapy in HIV-associated multicentric Castleman disease.
Bower M; Veraitch O; Szydlo R; Charles P; Kelleher P; Gazzard B; Nelson M; Stebbing J
Blood; 2009 May; 113(19):4521-4. PubMed ID: 19224759
[TBL] [Abstract][Full Text] [Related]
12. [Recurrent infections in an ITP patient treated with rituximab].
Rosenberg-Bezalel S; Asher I; Sthoeger Z
Harefuah; 2012 Nov; 151(11):617-9, 655. PubMed ID: 23367730
[TBL] [Abstract][Full Text] [Related]
13. [Rituximab treatment for adults with steroid-resistant idiopathic thrombocytopenic purpura].
Wang W; Yu QH; Zhang HY; Chu XX; Chen F; Zhang CQ; Zhou YH; Hou M
Zhonghua Nei Ke Za Zhi; 2008 Mar; 47(3):225-7. PubMed ID: 18785508
[TBL] [Abstract][Full Text] [Related]
14. Treatment of unicentric Castleman disease with neoadjuvant rituximab.
Bandera B; Ainsworth C; Shikle J; Rupard E; Roach M
Chest; 2010 Nov; 138(5):1239-41. PubMed ID: 21051400
[TBL] [Abstract][Full Text] [Related]
15. A Multicentric Castleman Disease Associated with Mixed Warm and Cold Antibody-Mediated AHA Responsive to Siltuximab.
Plano F; Mancuso S; Camarda GM; Butera MG; Sucato G; Alecci G; Florena AM; Perrone S; Siragusa SM
Chemotherapy; 2024; 69(1):35-39. PubMed ID: 37634492
[TBL] [Abstract][Full Text] [Related]
16. B-cell depletion with rituximab as treatment for immune hemolytic anemia and chronic thrombocytopenia.
Zaja F; Iacona I; Masolini P; Russo D; Sperotto A; Prosdocimo S; Patriarca F; de Vita S; Regazzi M; Baccarani M; Fanin R
Haematologica; 2002 Feb; 87(2):189-95. PubMed ID: 11836170
[TBL] [Abstract][Full Text] [Related]
17. Sustained response to anti-CD20 monoclonal antibody in severe acute primary immune thrombocytopenic purpura: report of one adult case.
Luzzatto G; Cella G; Fabris F
Clin Appl Thromb Hemost; 2006 Jan; 12(1):120-1. PubMed ID: 16444448
[No Abstract] [Full Text] [Related]
18. Complete remission in a pancytopenic HIV negative, HHV-8 positive patient with multicentric Castleman's disease induced with anti-CD20.
Cervera Grau JM; Galiana Esquerdo G; Llorca Ferrándiz C; Briceño García H; Díaz Castellano M; Férriz Moreno P
Clin Transl Oncol; 2006 Jul; 8(7):540-1. PubMed ID: 16870545
[TBL] [Abstract][Full Text] [Related]
19. Rituximab for the treatment of refractory idiopathic thrombocytopenic purpura (ITP) and thrombotic thrombocytopenic purpura (TTP): report of three cases.
Koulova L; Alexandrescu D; Dutcher JP; O'Boyle KP; Eapen S; Wiernik PH
Am J Hematol; 2005 Jan; 78(1):49-54. PubMed ID: 15609292
[TBL] [Abstract][Full Text] [Related]
20. The efficacy and safety of B-cell depletion with anti-CD20 monoclonal antibody in adults with chronic immune thrombocytopenic purpura.
Cooper N; Stasi R; Cunningham-Rundles S; Feuerstein MA; Leonard JP; Amadori S; Bussel JB
Br J Haematol; 2004 Apr; 125(2):232-9. PubMed ID: 15059147
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
